FindTrial
Sign In

pharmacogenomics researches on type 2 diabetes

Study on the Pharmacogenomics of Type 2 Diabetes Mellitus and Validation Scheme of NGS Sequencing Results in Patients with Endpoint Events

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800015661
Enrollment
Unknown
Registered
2018-04-13
Start date
2018-04-28
Completion date
Unknown
Last updated
2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Case series:no Intervention

Sponsors

Institute of Clinical Pharmacology, Central South University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with type 2 diabetes and having diabetes complications; 2. Aged 18-80 years old; 3. Patients undergoing oral hypoglycemic therapy.

Exclusion criteria

Exclusion criteria: 1. Patients with type 1 diabetes or other types of diabetes; 2. Severe cardiovascular and cerebrovascular diseases caused by non-diabetes, patients with liver and kidney disease; 3. Loss of patients.

Design outcomes

Primary

MeasureTime frame
complications of diabetes;Genetic sequence;—

Countries

China

Contacts

Public ContactWei Zhang

Central South University

yjsd2003@163.com+86 13973168774

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026